18 and older, any sex, with Obesity or Primary Care. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Treatment Acceptability QuestionnairePrimary· Immediately after appointment (Same day as intervention delivery)
Intervention participants reported acceptability, as measured by the Treatment Acceptability Questionnaire (Hunsley, 1992). This is a 6-item scale that asks the participant to rate several metrics of acceptability with Likert scale responses (individual items range 1-7, one item is reverse scored). A higher score indicates greater acceptability, a score of 21 is the benchmark for acceptability. Overall range of 6-42.
Group
Value
95% CI
Intervention
35.8
± 5.5
Feasibility of Recruitment From Primary Care Waiting Room and Intervention DeliveryPrimary· When study staff is recruiting in the office during the data collection period, approx. 20 days over 6 months
Study flow will be tracked by study staff and compared to pre-determined benchmarks. 1) Percentage of patients who indicate verbal consent for screening (benchmark \>70%), 2) percentage of eligible participants after screening (benchmark \>50%), 3) percentage of participants who refuse to participate because of focus on weight (benchmark \<20%), 4)percentage of participants who complete the experiential pamphlet (benchmark \>80%).
Percentage of participants indicated verbal consent for screening
Group
Value
95% CI
Feasibility, Tracked by Participant Flow
60
Percentage of eligible participants after screening
Group
Value
95% CI
Feasibility, Tracked by Participant Flow
53.5
Percentage of screened participants who refuse to participate because of focus on weight
Group
Value
95% CI
Feasibility, Tracked by Participant Flow
0
Percentage of participants who complete the experiential pamphlet
Group
Value
95% CI
Feasibility, Tracked by Participant Flow
86.2
If Weight Was Spoken About in the AppointmentSecondary· Immediately after appointment (Same day as intervention delivery)
Participants respond to Yes/No questions about content of their appointment
Patient-initiated weight discussion occured
Group
Value
95% CI
Intervention
7
Control
5
Patient- or physician-initiated weight discussion occurred
Group
Value
95% CI
Intervention
14
Control
11
Sponsor's own description
This study tests the feasibility, acceptability, and preliminary efficacy of using a brief pamphlet in the primary care waiting room focused on promoting patient-initiated weight-related discussions in primary care appointments.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07403604 — Effect of Insulin Lowering on Lipogenesis
· Phase 1
· recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee
· Phase 3
· recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
· recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart
· Phase 3
· recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl
· Phase 1
· recruiting
Other Drexel University trials
Trials by the same sponsor.
NCT07022808 — Tele-Exercise to Promote Empowered Movement in Individuals With Spinal Cord Injury
· NA
· not yet recruiting
NCT07165522 — Centering Autistic Perspectives in Behavioral Intervention Discussions
· NA
· not yet recruiting
NCT07225881 — Eatwell Clinical Trial (R01)
· NA
· recruiting
NCT06690372 — Improving Heart Health in Individuals With SCI Using Home-Based Virtual Gaming
· NA
· not yet recruiting
NCT06972381 — Piloting a Patient Navigator Program for Weight Loss
· NA
· active not recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Drexel University
Last refreshed: 6 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04486235.